Retrospective Analysis of a Psoralea Corylifolia (Buguzhi)-Containing TCM Formula for Gastrointestinal Cancers
Key facts
- Who runs it
- Peking University Cancer Hospital & Institute
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 120 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Treatments tested
- Psoralea corylifolia-Containing TCM Formula
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Pathologically confirmed diagnosis of Gastrointestinal cancers, including esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, or colorectal cancer
- Received TCM formulas containing Psoralea corylifolia as part of routine clinical care
- Available baseline and post-treatment imaging (CT or MRI) for RECIST 1.1 response assessment
- Available KPS performance status records before and after treatment
- Complete clinicopathologic and follow-up data
Who cannot take part
- Concurrent other active malignancies
- Incomplete medical records or missing imaging data
- Less than 4 weeks of TCM formula treatment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Psoralea corylifolia (Buguzhi) is a traditional Chinese medicine (TCM) herb with reported anti-tumor activity; its major bioactive compound, isobavachalcone (IBC), has been shown to inhibit ADORA3 and the downstream FAK/AKT/NF-κB signaling axis in gastrointestinal cancers. This is a retrospective, single-arm observational study reviewing medical records of approximately 120 patients with gastrointestinal cancers (esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, and colorectal cancer; n=30 each) treated at Peking University Cancer Hospital who received TCM formulas containing Psoralea corylifolia as part of routine clinical care. The study evaluates changes in tumor response assessed by RECIST version 1.1 and in Karnofsky Performance Status (KPS) between baseline and 8-12 weeks after initiation of treatment.
The group in the trial
- Psoralea corylifolia (Buguzhi)-Containing TCM Formula
Patients with gastrointestinal cancers (esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), hepatocellular carcinoma (HCC), and colorectal cancer (CRC)) who received TCM formulas containing Psoralea corylifolia (Buguzhi) as part of routine clinical care.
Treatment: Psoralea corylifolia-Containing TCM Formula
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Retrospective Observational Study on the Clinical Efficacy of a Traditional Chinese Medicine Formula Containing Psoralea Corylifolia (Buguzhi) in Patients With Gastrointestinal Cancers
- Record updated
- 12 November 2026